Universal Bacterium-Vectored COVID-19 Vaccine Expressing Early SARS-CoV-2 Conserved Proteins Cross-Protects Against Late Variants in Hamsters.

Qingmei Jia, Helle Bielefeldt-Ohmann, Saša Masleša-Galić, Richard A Bowen, Marcus A Horwitz

Abstract read

In one paragraph

Article in Vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Qingmei JiaDivision of Infectious Diseases, Department of Medicine, 32-150 Center for Health Sciences, School of Medicine, University of California-Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA.

Helle Bielefeldt-OhmannAustralian Infectious Diseases Research Centre, University of Queensland, St Lucia, QLD 4072, Australia.ORCID 0000-0002-5332-5445

Saša Masleša-GalićDivision of Infectious Diseases, Department of Medicine, 32-150 Center for Health Sciences, School of Medicine, University of California-Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA.

Richard A BowenDepartment of Biomedical Sciences, Colorado State University, Fort Collins, CO 80523, USA.

Marcus A HorwitzDivision of Infectious Diseases, Department of Medicine, 32-150 Center for Health Sciences, School of Medicine, University of California-Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA.ORCID 0000-0001-6525-7147

Funding

Development of a Safe and Potent Vaccine Against Melioidosis using the LVS dcapB Vector PlatformR01AI141390 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI HORWITZ, MARCUS AARON · 2019 to 2023

$3.9M

NIAID NIH HHS R01 AI141390NIH HHS 1R01AI141390-20

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19Delta variantLVS ΔcapB vectormembrane proteinnucleocapsid proteinOmicron variantRdRpSARS-CoV-2single-vector platformvaccine

Identifiers

PMID40573964

DOI10.3390/vaccines13060633

PMCPMC12197694

What Socratic holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.